Clinical Trial

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

Study acronym: LIGHT-MCI
Completed
View on ClinicalTrials.gov →
Summary
This is an investigator-led prospective, randomized, open label, parallel study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function in T2DM patients with mild cognitive impairment (MCI), consisting of a 48-week core study followed by a 28-week extension phase.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-24
minor Completion moved earlier: 2026-07-31 -> 2026-07-01 2026-07-24
Trial Details
NCT Number NCT05313529
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: Nanjing First Hospital, Nanjing Medical University, The Affiliated Jiangning Hospital of Nanjing Medical University, Wuxi People's Hospital, Changzhou No.2 People's Hospital
Conditions Type 2 Diabetes Mellitus, Mild Cognitive Impairment
Enrollment 396 participants
Start Date 2022-10-08
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06